J. Safra Sarasin Holding AG Sells 5,908 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

J. Safra Sarasin Holding AG decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 64.7% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 3,230 shares of the biopharmaceutical company’s stock after selling 5,908 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Alnylam Pharmaceuticals were worth $1,069,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. iA Global Asset Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares in the last quarter. Perpetual Ltd purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $2,004,000. Linden Advisors LP purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $6,550,000. Hussman Strategic Advisors Inc. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $2,505,000. Finally, Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $281.26 on Wednesday. The stock has a market capitalization of $37.55 billion, a PE ratio of 76.85 and a beta of 0.27. The business has a 50 day simple moving average of $295.45 and a two-hundred day simple moving average of $323.24. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 1-year low of $273.11 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.44) EPS. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ALNY shares. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a research report on Friday, July 10th. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Bank of America cut their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Citigroup assumed coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $455.31.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.